Clinical trials: Neoadjuvant Treatment
Breast Cancer
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab…
- Trial name
- NCT00203372
- Testing
- Bevacizumab 7.5 and TAC, Bevacizumab 15 and TAC
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 6 people
- Sponsor
- Translational Oncology Research International
Colorectal Cancer, Colon Cancer
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
AIO-KRK-0420 NeoBRAF is a single arm, multicenter, phase II trial with neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer.
- Conditions
- Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation
- Trial name
- NeoBRAF (NCT05510895)
- Testing
- Binimetinib
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- AIO-Studien-gGmbH
Breast Cancer
Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging
This study seeks to enroll women with breast cancer undergoing neoadjuvant chemotherapy to evaluate if Diffuse Optical Spectroscopy Imaging (DOSI) can predict a patient response to chemotherapy treatment.
- Trial name
- DOSI (NCT02510456)
- Testing
- Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort, Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston Medical Center
Breast Cancer
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
It has been found that many breast cancers are hormone dependent and that hormonal therapy by estrogen suppression such as ovarian ablation, tamoxifen and aromatase inhibitor has proven beneficial in both adjuvant and neoadjuvant…
- Trial name
- NCT00488722
- Testing
- Zoladex
- Where
- China
- Sponsor
- Tianjin Medical University
Rectal Cancer
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
This study is a one-year, observational, prospective cohort study. For enrolled patients with newly diagnosed locally advanced rectal cancer, the treatment plan will be decided by the physician based on the 2022 NCCN Rectal…
- Trial name
- NCT07346729
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer
Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer
- Trial name
- Opti-HER (NCT01669239)
- Testing
- Liposomal Doxorubicin
- Where
- 19 sites in Spain
- Volunteers
- 83 people
- Sponsor
- SOLTI Breast Cancer Research Group
Pancreatic Cancer
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new…
- Trial name
- NCT04452357
- Testing
- PLDR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Drug Effect
The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients
Neoadjuvant chemotherapy for breast cancer could make unresectable breast cancer be resectable and improve breast conservation rate.
- Trial name
- NCT04131881
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 245 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
This prospective, single-arm, Phase II clinical trial aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy and postoperative adjuvant immunotherapy in patients with skull…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
- Trial name
- NCT07145931
- Testing
- Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
- Trial name
- BRANCH (NCT01481545)
- Testing
- Radiation therapy, Oxaliplatin, Raltitrexed
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute, Naples
Esophagus Cancer
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy.
- Trial name
- NCT07063901
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Central South University
Gastric Cancer
Pre-rehabilitation in Neoadjuvant Patients With Gastric Cancer
In this study, patients with traditional neoadjuvant gastric cancer were used as controls to explore whether the triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period before…
- Trial name
- NCT05445401
- Testing
- Pre-rehabilitation, Standard medical care
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Advanced Rectal Cancer
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
The study evaluate the addition of Irinotecan in neoadjuvant chemoradiation. Half of participants will receive capecitabine alone together with neoadjuvant CRT, followed by a cycle of XELOX, while the other will receive…
- Trial name
- CinClare (NCT02605265)
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Fudan University
Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab
- Trial name
- NCT07787273
- Testing
- Interferon-γ, Camrelizumab
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Hefei Cancer Hospital of the Chinese Academy of Sciences
Breast Cancer
Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
This is a prospective, single-center cohort study enrolling patients with axillary lymph node-positive or locally advanced breast cancer, consistent with the indications for neoadjuvant therapy in routine clinical practice and as…
- Trial name
- NCT07553741
- Testing
- 68Ga-FAPI-04, 18F-FDG
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Colorectal Cancer
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
This is a prospective, open-label, single-center, phase II umbrella trial designed to evaluate the efficacy and safety of neoadjuvant therapy for locally advanced colorectal cancer.
- Trial name
- NCT07503639
- Testing
- SHR-1701, SHR-8068, Short-course radiotherapy
- Volunteers
- 134 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma, Ivonescimab
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
- Trial name
- NCT07385001
- Testing
- AK112, AK112 + Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tang-Du Hospital
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.